| NCT ID | NCT07087821 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2025-09-16 |
| Primary Completion | 2027-09-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2025-09-16 with a primary completion date of 2027-09-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators will conduct two-arm randomized controlled trials (RCTs) comparing effects of UPLIFT vs. enhanced usual care and PACES vs. enhanced usual care, respectively, on quality of life, depressive symptoms and seizures over 12 months in NYU patients with epilepsy.
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years) * English-speaking (UPLIFT and PACES) or Spanish-speaking (UPLIFT only). * Diagnosed with epilepsy for at least one year * Able to understand the informed consent and provide consent * Elevated depressive symptoms - Patient Health Questionnaire-9 (PHQ-9) score ≥10; applies to UPLIFT only Exclusion Criteria: * Severe depressive symptoms (score of ≥20 on PHQ-9) * Active suicidal ideation (score of ≥1 on PHQ-9 item #9 or otherwise reported during screening) * Active psychotic disorder (psychiatric diagnosis and/or antipsychotic medications in the electronic health records (EHR) * Significant cognitive impairment (indicated in the EHR or evident during screening)
Contact & Investigator
Tanya Spruill, PhD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT07087821 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07087821 currently recruiting?
Yes, NCT07087821 is actively recruiting participants. Contact the research team at Tanya.Spruill@nyulangone.org for enrollment information.
Where is the NCT07087821 trial being conducted?
This trial is being conducted at Brooklyn, United States, New York, United States.
Who is sponsoring the NCT07087821 clinical trial?
NCT07087821 is sponsored by NYU Langone Health. The principal investigator is Tanya Spruill, PhD at NYU Langone Health. The trial plans to enroll 108 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.